Get actionable insights in prostate cancer

Hereditary cancer genetic testing helps identify high-risk patients.1,2 Invitae makes it easy.
Middle aged black male bald with gray beard
Graphic illustration showing 1 in 6 men with prostate cancer has a hereditary genetic variant

1 in 6

patients with prostate cancer has a hereditary genetic variant²

Individual risk stratification in prostate cancer is essential to building a personalized care plan for every patient.1,3 Integrating hereditary cancer genetic testing into your initial clinical assessment can give you more information about a patient’s risk of aggressive disease right from the start.1,4
Graphic illustration showing 16% more men develop metastases with BRCA at 5 years

Early detection of a hereditary cancer genetic variant can make a difference

High-risk genetic variants are associated with more biologically aggressive prostate cancer.1,5 Early detection may give your patients a better chance at improved outcomes.1,4 In metastatic cases, survival among men with a BRCA1 or BRCA2 variant is half that of men with no genetic variant.6

Hereditary prostate cancer genetic testing helps you know when to wait and when to act

Genetic testing can reveal a patient's potential risk of more aggressive disease to help inform next steps.1

Prioritize patients for biopsy⁵﹐⁷

Icon computer

Validate patient PSA results⁴﹐⁷


Place patients on active surveillance³


Flag patients who need more immediate intervention, including surgery, radiation or clinical trials¹﹐⁵﹐⁸

Pie chart shows guidelines miss up to 70% of men with a hereditary genetic variant

Family history is not enough—by testing everyone, you overlook no one

Many patients with prostate cancer who have genetic variants have no suggestive family history.1 In fact, as many as 70% of men with advanced or metastatic prostate cancer who had an actionable pathogenic hereditary cancer variant didn’t qualify for genetic testing based on family history.9

Testing beyond prostate cancer guidelines helps identify patients with high-risk variants that may otherwise go undetected.1

Test today for their tomorrow

Want to learn more?

BRCA1 and BRCA2=breast cancer genes
PSA=prostate-specific antigen

1. Nicolosi P, Ledet E, Yang S, et al. Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines. JAMA Oncol. 2019;5(4):523-528. doi:10.1001/jamaoncol.2018.6760
2. Samadder NJ, Riegert-Johnson D, Boardman L, et al. Comparison of universal genetic testing vs guideline-directed targeted testing for patients with hereditary cancer syndrome. JAMA Oncol. 2021;7(2):230-237. doi:10.1001/jamaoncol.2020.6252
3. Carroll PH, Mohler JL. NCCN Guidelines updates: prostate cancer and prostate cancer early detection. J Natl Compr Canc Netw. 2018;16(5.5):620-623. doi: 10.6004/jnccn.2018.0036
4. Giri VN, Knudsen KE, Kelly WK, et al. Implementation of germline testing for prostate cancer: Philadelphia Prostate Cancer Consensus Conference 2019. J Clin Oncol. 2020;38(24):2798-2811. doi: 10.1200/JCO.20.00046
5. Castro E, Goh C, Olmos D, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol. 2013;31(14):1748-1757. doi: 10.1200/JCO.2012.43.1882
6. Lowrance WT, Breau RH, Chou R, et al. Advanced prostate cancer: AUA/ASTRO/SUO Guideline PART II. J Urol. 2021;205:22-29. doi: 0.1097/JU.0000000000001376
7. Bancroft EK, Page EC, Castro E, et al. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. Eur Urol. 2014;66(3):489-499. doi: 10.1016/j.eururo.2014.01.003
8. Giri VN, Hyatt C, Leader A. Cancer screening and genetic testing recommendations for relatives of men undergoing prostate cancer germline testing: implications for practice. J Urol. 2020;204(6):1116-1118. doi: 10.1097/JU.0000000000001150
9. Mandelker D, Zhang L, Kemel Y, et al. Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing. JAMA. 2017;318(9):825-835. doi: 10.1001/jama.2017.11137